Inhibace - Product Information
|Condition:||Heart Failure (Congestive Heart Failure), High Blood Pressure (Hypertension), Hypertension (High Blood Pressure)|
|Ingredients:||Cilazapril, Lactose monohydrate, Cornstarch, Hydroxypropyl methylcellulose, Talc, Sodium stearyl fumarate, Titanium dioxide, Iron oxide|
Summary Product Information
|Route of Administration||Dosage Form / Strength||Nonmedicinal Ingredients|
|Oral||tablet 2.5 mg, 5 mg||Lactose monohydrate, cornstarch, hydroxypropyl methylcellulose, talc, sodium stearyl fumarate and titanium dioxide. Iron oxide is present as the colouring agent in the tablet.|
Indications and Clinical Use
INHIBACE (cilazapril) is indicated in the treatment of mild to moderate essential hypertension. INHIBACE may be used alone or in combination with thiazide-type diuretics. INHIBACE is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics.
In using INHIBACE consideration should be given to the risk of angioedema (see WARNINGS AND PRECAUTIONS).
INHIBACE should normally be used in those patients in whom treatment with a diuretic or a beta-blocker was found ineffective or has been associated with unacceptable adverse effects.
INHIBACE can also be tried as an initial agent in those patients in whom use of diuretics and/or beta-blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects.
The safety and efficacy of INHIBACE in renovascular hypertension has not been established and therefore, its use in this condition is not recommended.
The safety and efficacy of concomitant use of INHIBACE with antihypertensive agents other than thiazide diuretics has not been established.
Congestive Heart Failure
INHIBACE is indicated in the treatment of congestive heart failure as adjunctive therapy in patients who have not responded adequately to digitalis and/or diuretics. There is limited data on New York Heart Association Class IV patients (see ACTIONS AND CLINICAL PHARMACOLOGY). Treatment with INHIBACE should be initiated in patients with congestive heart failure under close medical supervision.
Although clinical experience has not identified differences in response between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. In elderly patients with congestive heart failure on high diuretic dosage, the recommended starting dose of INHIBACE 0.5 mg must be strictly followed (see WARNINGS AND PRECAUTIONS, Geriatrics).
The safety and effectiveness of the use of INHIBACE in children have not been established. Therefore, use in this age group is not recommended.
INHIBACE (cilazapril) is contraindicated in:
- Patients who are hypersensitive to cilazapril, any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
- Patients with hereditary/idiopathic angioedema or a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor (see WARNINGS AND PRECAUTIONS, General).
- Patients with anuria
- Patients with ascites
- Women who are pregnant, intend to become pregnant, or of childbearing potential who are not using adequate contraception (see WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions and Special Populations, Pregnant Women and ADVERSE REACTIONS).
- Nursing Women (see WARNINGS AND PRECAUTIONS: Special Populations, Nursing Women).
- Combination with aliskiren-containing drugs in patients with:
- diabetes mellitus (type 1 or type 2)
- moderate to severe renal impairment (GFR < 60 ml/min/1.73 m2) (see WARNINGS and PRECAUTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) and Renal, and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs).
- Patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency as INHIBACE® contains lactose (see WARNINGS AND PRECAUTIONS, Sensitivity/Resistance)
Warnings and Precautions
Serious Warnings and Precautions
The use of INHIBACE (cilazapril) is contraindicated during pregnancy (see CONTRAINDICATIONS). When used in pregnancy, angiotensin converting enzyme (ACE) inhibitors can cause injury or even death of the developing fetus. Pregnant women should be informed of the potential hazards to the fetus and must not take INHIBACE during pregnancy. Patients planning pregnancy should be changed to alternative antihypertensive treatments whichhave an established safety profile for use in pregnancy. When pregnancy is detected, INHIBACE should be discontinued as soon as possible and, if appropriate, alternative therapy should be started (see WARNINGS AND PRECAUTIONS).
Angioedema has been reported in patients treated with angiotensin-converting enzyme inhibitors including INHIBACE. Angioedema has been associated with ACE inhibitors, with a reported incidence of 0.1-0.5%. Angioedema due to ACE inhibitors can present as recurrent episodes of facial swelling, which resolve on withdrawal, or as acute oropharyngeal edema and potentially life-threatening airway obstruction, which requires emergency treatment. Angioedema associated with laryngeal edema and/or shock may be fatal. If angioedema occurs, INHIBACE (cilazapril) should be promptly discontinued and appropriate therapy instituted without delay. A variant form is angioedema of the intestine, which tends to occur within the first 24-48 hours of treatment.
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at an increased risk of angioedema while receiving an ACE inhibitor (see CONTRAINDICATIONS).
Concomitant use of ACE inhibitors with mammalian target of rapamycin (mTOR) inhibitors or dipeptidyl peptidase IV (DPP-IV) inhibitors may lead to an increased risk for angioedema. Caution should be used when using mTOR inhibitors or DPP-IV inhibitors concomitantly with ACE inhibitors (see DRUG INTERACTIONS, Drug-Drug Interactions).
Aortic Stenosis/Hypertrophic Cardiomyopathy
As with other ACE inhibitors, INHIBACE should be used with caution in patients with obstructive cardiac disorders (e.g. mitral stenosis, aortic stenosis, hypertrophic cardiomyopathy), since cardiac output cannot increase to compensate for systemic vasodilation, and there is a risk of severe hypotension.
There is concern on theoretical grounds that patients with aortic stenosis might be at particular risk of decreased coronary perfusion when treated with vasodilators because they do not develop as much afterload reduction.
INHIBACE, like other ACE inhibitors, may cause severe hypotension, especially when starting treatment, usually after the first dose or when the dose had been increased. First-dose hypotension is most likely to occur in patients whose renin-angiotensin-aldosterone system is activated, such as in renovascular hypertension or other causes of renal hypoperfusion, sodium or volume depletion, previous treatment with other vasodilators and in patients with dietary salt restriction, dialysis, diarrhea, or vomiting. These conditions can co-exist, particularly in severe heart failure.
Patients with congestive heart failure, especially those vigorously treated with loop diuretics, may experience excessive hypotension in response to ACE inhibitors. Because of the potential fall in blood pressure in these patients, therapy should be started under very close medical supervision. Such patients should be followed closely for the first two weeks of treatment and whenever the dose of INHIBACE and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident (see ADVERSE REACTIONS).
Patients at risk for hypotension should start treatment with cilazapril under medical supervision, with a low initial dose and careful titration. If possible, diuretic therapy should be discontinued temporarily.
Similar caution should be taken for patients with angina pectoris or cerebrovascular disease, in whom hypotension can cause myocardial or cerebral ischemia.
In patients with severe heart failure, whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with ACE inhibitors, including INHIBACE, may be associated with oliguria and/or progressive azotemia and rarely acute renal failure and/or death.
Hypotension should be treated by placing the patient supine and with volume expansion. Cilazapril may be continued once the patient is volume replete, but should be given at a lower dose or discontinued if hypotension persists.
Dual Blockade of the Renin-Angiotensin System (RAS)
There is evidence that co-administration of angiotensin converting enzyme (ACE) inhibitors, such as INHIBACE, or of angiotensin receptor antagonists (ARBs) with aliskiren increases the risk of hypotension, syncope, stroke, hyperkalemia and deterioration of renal function, including renal failure, in patients with diabetes mellitus (type 1 or type 2) and/or moderate to severe renal impairment (GFR < 60 ml/min/1.73m2). Therefore, the use of INHIBACE in combination with aliskiren-containing drugs is contraindicated in these patients (see CONTRAINDICATIONS). Further, co-administration of ACE inhibitors, including INHIBACE, with other agents blocking the RAS, such as ARBs or aliskiren-containing drugs, is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia.
A dry, persistent cough, which usually disappears only after withdrawal or lowering of the dose of INHIBACE, has been reported.
Such possibility should be considered as part of the differential diagnosis of the cough.
Endocrine and Metabolism
Administration of ACE inhibitors to patients with diabetes may potentiate the blood glucose lowering effect of oral hypoglycemic agents or insulin, especially in patients with renal impairment. In such patients, glucose levels should be carefully monitored during initiation of treatment with an ACE inhibitor.
ACE inhibitors are less effective as antihypertensives in black-skinned patients of African descent. Black-skinned patients also have a higher risk of angioedema.
Agranulocytosis and bone marrow depression have been caused by ACE inhibitors. Cases of leucopenia and neutropenia have rarely been reported in patients treated with ACE Inhibitors.
Periodic monitoring of white blood cell counts should be considered in patients with collagen vascular disease and renal disease such as systemic lupus erythematosus and scleroderma, or in patients receiving immunosuppressive therapy, especially when they also have impaired renal function.
Patients With Impaired Liver Function
Hepatitis (hepatocellular and/or cholestatic), jaundice, elevations of liver enzymes and/or serum bilirubin have occurred during therapy with cilazapril in patients with or without pre-existing liver abnormalities. In most cases the changes were reversed on discontinuation of the drug.
Cases of liver function disorders, such as increased values of liver function tests (transaminases, bilirubin, alkaline phosphatase, gamma GT) and cholestatic hepatitis have been reported. Patients receiving cilazapril who develop jaundice or marked elevations of hepatic enzymes should discontinue cilazapril and receive appropriate medical follow-up.
There are no adequate studies in patients with cirrhosis and/or liver dysfunction. INHIBACE should be used with particular caution in patients with pre-existing liver abnormalities. In such patients baseline liver function tests should be obtained before administration of the drug and close monitoring of response and metabolic effects should apply.
In patients with liver cirrhosis (but without ascites) who require therapy for hypertension, cilazapril should be initiated at a lower dose and with great caution because significant hypotension may occur. In patients with ascites, cilazapril administration is not recommended.
Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death. The mechanism of this syndrome is not understood.
ACE inhibitors can cause hyperkalemia because they inhibit the release of aldosterone. The effect is usually not significant in patients with normal renal function. However, in patients with impaired renal function and/or in patients taking potassium supplements (including salt substitutes) or potassium-sparing diuretics, and especially aldosterone antagonists, hyperkalemia can occur. Potassium-sparing diuretics should be used with caution in patients receiving ACE inhibitors, and serum potassium and renal function should be monitored.
In clinical trials, elevated serum potassium (greater than 5.5 mEq/L) was observed in approximately 0.7% of hypertensive patients and 0.8% of congestive heart failure patients receiving cilazapril. In most cases these were isolated values which resolved despite continued therapy, however in one case the patient discontinued treatment. Risk factors for the development of hyperkalemia may include renal insufficiency, diabetes mellitus, and the concomitant use of agents to treat hypokalemia (see DRUG INTERACTIONS and ADVERSE REACTIONS).
Anaphylactoid Reactions during Membrane Exposure
Hemodialysis: Anaphylactoid reactions have been reported in patients dialysed with high-flux membranes (e.g., polyacrylonitrile [PAN], AN 69) and treated concomitantly with an ACE inhibitor. Dialysis should be stopped immediately if symptoms such as nausea, abdominal cramps, burning, angioedema, shortness of breath and severe hypotension occur. Symptoms are not relieved by antihistamines. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent.
Anaphylactoid Reactions during Low Density Lipoproteins (LDL) Apheresis
Patients receiving ACE inhibitors during LDL apheresis with dextran sulfate have experienced life-threatening anaphylactoid reactions. These reactions can be avoided by temporarily withholding ACE inhibitor therapy prior to each apheresis.
Anaphylactoid Reactions during Desensitization
There have been reports of patients experiencing sustained life threatening anaphylactoid reactions while receiving ACE inhibitors during desensitizing treatment with hymenoptera (bees, wasps) venom. In the same patients, these reactions have been avoided when ACE inhibitors were temporarily withheld for at least 24 hours, but they have reappeared upon inadvertent rechallenge.
Cilazapril use must be stopped before the start of desensitization therapy and must not be replaced by a beta-blocker.
Nitritoid Reactions – Gold
Nitritoid reactions (symptoms include facial flushing, nausea, vomiting, and symptomatic hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including INHIBACE (see DRUG INTERACTIONS).
In patients undergoing major surgery or during anesthesia with agents that produce hypotension, cilazapril blocks angiotensin II formation, secondary to compensatory renin release. This may result in arterial hypotension which can be corrected by volume expansion.
As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function have been seen in susceptible individuals. In patients whose renal function may depend on the activity of the renin-angiotensin aldosterone system, rarely, acute renal failure have been reported such as patients with bilateral renal artery stenosis, unilateral renal artery stenosis to a solitary kidney, or severe congestive heart failure, treatment with agents that inhibit this system has been associated with oliguria, progressive azotemia, and rarely, acute renal failure and/or death. In susceptible patients, concomitant diuretic use may further increase risk and produce increases in blood urea nitrogen and/or serum creatinine. Although these alterations are usually reversible upon discontinuation of INHIBACE and/or diuretic therapy, cases of severe renal dysfunction and, rarely, acute renal failure have been reported. In susceptible patients, concomitant diuretic use may further increase risk.
When treated with cilazapril, patients with renal artery stenosis have an increased risk of renal insufficiency, including acute renal failure. Therefore, caution should be exercised in these patients.
Use of INHIBACE should include appropriate assessment of renal function.
Reduced dosages may be required for patients with renal impairment depending on their creatinine clearance (see DOSAGE AND ADMINISTRATION, Dosage Adjustment in Patients with Renal Impairment).
The use of ACE inhibitors – including INHIBACE – or ARBs with aliskiren-containing drugs is contraindicated in patients with moderate to severe renal impairment (GFR < 60 ml/min/1.73m2). (See CONTRAINDICATIONS and DRUG INTERACTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS) with ARBs, ACE inhibitors, or aliskiren-containing drugs).
INHIBACE tablets contain lactose monohydrate. Therefore, patients with hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine (see CONTRAINDICATIONS).
ACE inhibitors can cause fetal and neonatal morbidity and mortality when administered to pregnant women. The use of cilazapril is contraindicated during pregnancy. Pregnant women should be informed of the potential hazards to the fetus and must not take INHIBACE during pregnancy (see CONTRAINDICATIONS). Patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with ACE inhibitors should be stopped immediately, and, if appropriate, alternative therapy should be started.
Fetal exposure to ACE inhibitors during the first trimester of pregnancy has been reported to be associated with prematurity, an increased risk of malformations of the cardiovascular (atrial and/or ventricular septal defect, pulmonic stenosis, patent ductus arteriosus) and central nervous system (microcephaly, spina bifida) and of kidney malformations.
Exposure to ACE inhibitor therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (hypotension, hyperkalemia, neonatal skull hypoplasia, intrauterine growth restriction, anuria, renal tubular dysplasia, reversible or irreversible renal failure and death). Oligohydramnios reported with the use of ACE inhibitors presumably resulted from decreased fetal renal function, associated with fetal limb contractures, craniofacial deformation, and hypoplastic lung development. Should exposure to ACE inhibitors have occurred from the second trimester of pregnancy, ultrasound examination of renal function and skull is recommended. Infants whose mothers have taken ACE inhibitors should be closely observed for hypotension.
Infants with a history of in utero exposure to ACE inhibitors should be closely observed for hypotension, oliguria, and hyperkalemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as a means of reversing hypotension and/or substituting for impaired renal function; however, limited experience with those procedures has not been associated with significant clinical benefit.
Dialysis clearance was estimated to be 2.4 L/h for cilazapril and 2.2-2.8 L/h for cilazaprilat.
In fertility and general reproduction performance testing in rats, dosing with 50 mg/kg/day of cilazapril resulted in greater implantation losses, less viable fetuses, smaller pups, and dilatation of the renal pelvis in the pups. No teratogenic effects and no adverse effects on postnatal pup development were observed in rats and cynomolgus monkeys during embryotoxicity testing. In the rats, however, at a dose of 400 mg/kg/day, renal cavitation was observed in the pups. In peri- and post-natal toxicity testing in rats, dosing with 50 mg/kg/day resulted in greater pup mortality, smaller pups, and delayed unfolding of the pinna. On administration of C-cilazapril to pregnant mice, rats and monkeys, radioactivity was measured in the fetuses.
Animal data show the presence of cilazaprilat in rat milk. However, no information is available regarding the safety of cilazapril during breast-feeding in humans. INHIBACE must not be administered to nursing mothers (see CONTRAINDICATIONS) and alternative treatments with better established safety profiles during breast-feeding are preferable.
Ability to Drive and Use Machines
Occasionally dizziness and fatigue may occur, especially when starting therapy (see ADVERSE REACTIONS).
The safety and effectiveness of the use of INHIBACE in children have not been established. Therefore, use in this age group is not recommended.
Although clinical experience has not identified differences in response between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. In elderly patients with congestive heart failure on high diuretic dosage, the recommended starting dose of INHIBACE 0.5 mg must be strictly followed (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension, and DOSAGE AND ADMINISTRATION).
Adverse Drug Reaction Overview
Headache and dizziness were the most frequently reported events in patients taking INHIBACE for hypertension. In chronic heart failure clinical trials, dizziness and coughing were the most frequently reported events in patients taking INHIBACE.
The most frequent drug-attributable adverse events observed in patients taking ACE inhibitors are cough, skin rash and renal dysfunction. Cough is more common in women and non- smokers. Where the patient can tolerate the cough, it may be reasonable to continue treatment. In some cases, reducing the dose may help.
Treatment-related adverse events severe enough to stop treatment occur in less than 5% of patients receiving ACE inhibitors.
Hypotension and postural hypotension may occur when starting treatment or increasing dose, especially in at-risk patients (see WARNINGS AND PRECAUTIONS).
Renal impairment and acute renal failure are more likely in patients with severe heart failure, renal artery stenosis, pre-existing renal disorders or volume depletion (see WARNINGS AND PRECAUTIONS).
Hyperkalaemia is most likely to occur in patients with renal impairment and those taking potassium sparing diuretics or potassium supplements.
The events of cerebral ischaemia, transient ischaemic attack and ischaemic stroke reported rarely in association with ACE inhibitors may be related to hypotension in patients with underlying cerebrovascular disease. Similarly, myocardial ischaemia may be related to hypotension in patients with underlying ischaemic heart disease.
Headache is a commonly reported adverse event, although the incidence of headache is greater in patients receiving placebo than in those receiving ACE inhibitors.
Clinical Trial Adverse Drug Reactions
Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.
INHIBACE (cilazapril) has been evaluated for safety in 5,450 patients treated for essential hypertension and 1,106 patients treated for congestive heart failure.
Of these, 2,586 hypertensive and 900 congestive heart failure patients were treated with INHIBACE in controlled clinical trials. INHIBACE was evaluated for long-term safety in 798 hypertensive and 264 congestive heart failure patients treated for one year or longer.
The most serious adverse reactions reported in the 5,450 patients treated with INHIBACE for hypertension included: angioedema/face edema (0.1%) (see WARNINGS AND PRECAUTIONS, Cardiovascular, Angioedema), postural hypotension (0.3%), orthostatic hypotension (2.1%), myocardial infarction (0.1%), cerebrovascular disorder (0.04%), renal failure (0.09%), and thrombocytopenic purpura (0.02%).
In the 1,106 patients treated with INHIBACE for congestive heart failure, the most serious adverse reactions were: postural hypotension (1.6%), symptomatic hypotension (1.2%), myocardial infarction (0.3%), renal failure (0.1%) (see WARNINGS AND PRECAUTIONS, Renal), and cardiogenic shock (1 patient) (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).
Two elderly male patients, with a history of previous myocardial infarctions, on high diuretic dosage (240 mg and 120 mg of furosemide daily, respectively) for congestive heart failure NYHA Class III died within 8 hours after the addition of a single dose of 2.5 mg of INHIBACE (see WARNINGS AND PRECAUTIONS, Cardiovascular, Hypotension).
Hypotension and syncope, each reported in 0.1% of the hypertensive patients treated with INHIBACE, were reported in 2.1% and 0.8% of the congestive heart failure patients treated with INHIBACE.
Discontinuation of therapy was required in 63 (2.4%) of the hypertensive patients and 143 (12.9%) of the congestive heart failure patients.
See Table 1 for the most frequent adverse reactions reported in controlled clinical trials (> 1% and more frequent than in placebo treated patients).
|Congestive Heart Failure |
Less Common Clinical Trial Adverse Drug Reactions (<1%)
Other adverse reactions occurring in less than 1% of the 5,450 hypertension patients and the 1,106 congestive heart failure patients treated with INHIBACE were:
Cardiovascular: Chest pain, angina pectoris, tachycardia, atrial fibrillation, arrhythmia, flushing.
In the patient population treated with INHIBACE for congestive heart failure, there were reports of bradycardia, AV block, extra systoles, cardiac failure and cardiac decompensation.
Renal: Micturition frequency, polyuria, dysuria, uremia, renal pain.
Hematologic: Epistaxis, anemia, purpura.
Gastrointestinal : Dyspepsia, abdominal pain, diarrhea, constipation, vomiting, flatulence, GI bleeding, rectum bleeding, anorexia.
Dermatologic/Allergic: Rash (includes maculo-papular rash and erythematous rash), dermatitis, pruritus, urticaria, angioedema (including face edema).
Nervous System: Increased sweating, paresthesia, hypoesthesia, impotence, decreased libido, depression, anxiety, dry mouth, vertigo, migraine, tremor, dysphonia, ataxia, confusion, somnolence, insomnia, nervousness.
Musculoskeletal: Myalgia, leg cramps, arthralgia.
Special Senses: Tinnitus, abnormal vision, photophobia, conjunctivitis, taste perversion.
Respiratory: Rhinitis, sinusitis, pharyngitis, bronchitis, respiratory tract infection, dyspnea, bronchospasm.
In the congestive heart failure patient database the overall incidence of dyspnea was 3.1%. Dyspnea however was less frequent after INHIBACE than after placebo.
Body as a Whole: Malaise, hot flushes, pain, edema, rigors.
Abnormal Hematologic and Clinical Chemistry Findings
Patients had clinically relevant changes in platelet (0.4% and 0.7%), neutrophil (1.9% and 1.4%) or white blood cell counts (1.3% and 0.7%) while treated for hypertension and congestive heart failure respectively.
Leucopenia and neutropenia
Leucopenia was observed in 0.2% (10/3,580) and 0% (0/1,163) and neutropenia in 0.4% (22/5,720) and 0.6% (7/1,163) of the hypertensive and congestive heart failure patients respectively. Most of these were single transient occurrences; one case with two successive abnormalities showed no associated clinical symptoms.
Liver Function Tests
Clinically relevant changes in the values associated with liver function (SGOT, SGPT, GGTP, LDH, total bilirubin and alkaline phosphatase) occurred in 0.1% (bilirubin) to 1.1% (SGPT, GGTP) of the hypertensive patients and in 0.8% (LDH) to 2.9% (SGPT) of the congestive heart failure patients. Most of these abnormalities were transient. See WARNINGS AND PRECAUTIONS, Hepatic, Patients with Impaired Liver Function.
Clinically relevant changes in renal function test results (BUN or serum creatinine concentrations) occurred in 0.6% or less of the hypertensive patients and in 2.6% and 0.9% respectively of the congestive heart failure patients.
(see WARNINGS AND PRECAUTIONS)
Serum creatinine values > 2 mg/dL were reported in 1.3% (44/3,468) of the hypertensive patients. Two thirds of these patients had renal impairment at baseline. Serum creatinine values >2.8 mg/dL were reported in 0.4% (5/1,163) of the congestive heart failure patients. Of these, four of the five had abnormal serum creatinine values at baseline.
(>2+ dipstick reaction or excretion of > 1 g/24h): Proteinuria considered remotely, possibly or probably related to therapy was reported in 0.5% (17/3,421) of the hypertensive patients. Five patients had prior renal impairment. In congestive heart failure patients, 1.4% (16/1,106) experienced potentially clinically relevant proteinuria.
In congestive heart failure patients, hyperglycemia considered remotely, possibly or probably related to therapy was reported in 0.2% ( 2/1,106) patients.
Post-Market Adverse Drug Reactions
INHIBACE is usually well tolerated. In most cases, side effects are transient, mild or moderate in degree, and do not require discontinuation of therapy. The most common adverse effects include dry cough, rash, hypotension, dizziness, fatigue, headache, and nausea, dyspepsia and other gastrointestinal disturbances.
The following adverse reactions have been seen in association with cilazapril and/or other ACE inhibitors.
Frequency categories are as follows:
Very common ≥ 1/10
Common ≥ 1/100 and < 1/10
Uncommon ≥ 1/1,000 and < 1/100
Rare < 1/1,000
Blood and lymphatic systems disorders
Blood disorders have been reported with ACE Inhibitors and include neutropenia and agranulocytosis (especially in patients with renal failure and those with collagen vascular disorders such as systemic lupus erythematosus and scleroderma), thrombocytopenia, and hemolytic anemia.
Rare: Neutropenia, agranulocytosis, thrombocytopenia, anemia
Pronounced hypotension may occur at the start of therapy with ACE inhibitors, particularly in patients with heart failure and in sodium- or volume depleted patients. Myocardial infarction and stroke have been reported and may relate to severe falls in blood pressure in patients with ischaemic heart disease or cerebrovascular disease. Other cardiovascular effects that have occurred include tachycardia, palpitations, and chest pain.
Uncommon: Angina pectoris, tachycardia, palpitations Rare: Myocardial infarction
Uncommon: Hypotension (sometimes severe, see WARNINGS AND PRECAUTIONS) Symptoms of hypotension may include syncope, weakness, dizziness and visual impairment.
Respiratory, thoracic and mediastinal disorders
Common: Cough (sometimes severe)
As for other ACE inhibitors, isolated cases of pancreatitis, in some cases fatal, have been reported in patients treated with INHIBACE.
Rare: Abnormal liver function test including transaminases, bilirubin, alkaline phosphatase, gamma GT) and cholestatic hepatitis with or without necrosis.
Immune system disorders
As with other ACE inhibitors, angioneurotic edema has been reported, although rarely, in patients receiving INHIBACE. Since this syndrome can be associated with laryngeal edema, INHIBACE should be discontinued and appropriate therapy instituted without delay when involvement of the face, lips, tongue, glottis and/or larynx occurs.
Uncommon: Angioedema (may involve the face, lips, tongue, larynx or gastrointestinal tract) (see WARNINGS AND PRECAUTIONS).
Rare: Anaphylaxis (see WARNINGS AND PRECAUTIONS), Lupus-like syndrome (symptoms may include vasculitis, myalgia, arthralgia/arthritis, positive antinuclear antibodies, increased erythrocyte sedimentation rate, eosinophilia and leukocytosis).
Nervous system disorders
Rare: Transient ischaemic attack, ischaemic stroke (may be related in some cases to hypotension in patients with underlying cerebrovascular disease.)
Skin and subcutaneous tissue disorders
Skin rashes (including pemphigus, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis) may occur; photosensitivity, alopecia, and other hypersensitivity reactions have also been reported.
Rare: Toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, erythema multiforme, pemphigus, bullous pemphigoid, exfoliative dermatitis, psoriaform dermatitis, psoriasis (exacerbation), lichen planus, urticaria, vasculitis/purpura, photosensitivity reactions, alopecia, onycholysis.
Renal and urinary disorders
Cases of acute renal failure have been reported in patients with severe heart failure, renal artery stenosis or renal disorders (see WARNINGS AND PRECAUTIONS: Renal Impairment).
Rare: Renal impairment, acute renal failure, blood creatinine increased, blood urea increased, hyperkalemia, hyponatremia (see WARNINGS AND PRECAUTIONS, Renal).
General disorders and administration site conditions
Hypotension may occur when starting treatment or increasing dose, especially in at-risk patients (see WARNINGS AND PRECAUTIONS). Symptoms of hypotension may include syncope, weakness, dizziness and visual impairment.
Renal impairment and acute renal failure are more likely in patients with severe heart failure, renal artery stenosis, pre-existing renal disorders or volume depletion (see WARNINGS AND PRECAUTIONS).
Hyperkalemia is most likely to occur in patients with renal impairment and those taking potassium sparing diuretics or potassium supplements.
The events of transient ischemic attack and ischemic stroke reported rarely in association with ACE inhibitors may be related to hypotension in patients with underlying cerebrovascular disease. Similarly, myocardial ischemia may be related to hypotension in patients with underlying ischemic heart disease.
|Proper Name||Ref.||Effect||Clinical comment|
|Agents increasing serum potassium (potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes)||CT, C||Hyperkalemia may occur in some patients treated with INHIBACE. Potassium sparing diuretics (e.g. spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium impairment (see ACTION AND CLINICAL PHARMACOLOGY and WARNINGS AND PRECAUTIONS).||Therefore, the combination of cilazapril with agents increasing serum potassium (potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes) is not recommended (see WARNINGS AND PRECAUTIONS). If concomitant use is indicated severe hyperkalemia may occur they should be used with caution and with frequent monitoring of serum potassium.|
|Concomitant administration of ACE inhibitors and antidiabetic medicines (insulins, oral hypoglycaemic agents) may cause an increased blood-glucose-lowering effect with risk of hypoglycemia. This phenomenon appeared to be more likely to occur during the first weeks of combined treatment and in patients with renal impairment. |
Concomitant use of ACE inhibitors with DPP-IV inhibitors may lead to an increased risk for angioedema.
|Close monitoring of blood glucose levels is advised. |
See WARNINGS AND PRECAUTIONS, Cardiovascular, Angioedema
|Allopurinol, immunosuppressants, and steroid medicines||T||Concomitant administration with ACE inhibitors may lead to an increased risk of hematological reactions.||Increased likelihood of hematological reactions.|
|Digoxin||CT||No pharmacodynamic or pharmacokinetic interactions (and no increase in plasma digoxin concentrations) were observed when cilazapril therapy (5 mg once daily) was administered to healthy volunteers receiving digoxin (0.25 mg twice daily).|
|Diuretic therapy (thiazide or loop diuretics)||CT||Patients concomitantly taking ACE inhibitors and diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy.||The possibility of hypotensive effects after the first dose of INHIBACE can be minimized by either discontinuing the diuretic, or increasing the salt intake prior to initiation of treatment with INHIBACE. If it is not possible to discontinue the diuretic, the starting dose of INHIBACE should be reduced and the patient should be closely observed for several hours following the initial dose and until blood pressure has stabilized (see WARNINGS AND PRECAUTIONS and DOSAGE AND ADMINISTRATION).|
|Gold||C||Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.||Use with caution when INHIBACE is coadministered with gold salts.|
|Lithium Salts||CT||Reversible increases in serum lithium concentrations have been reported during concomitant administration of lithium with ACE inhibitors. Concomitant use of thiazide diuretics may increase the risk of lithium toxicity and enhance the already increased risk of lithium toxicity with ACE inhibitors. Lithium toxicity, including CNS symptoms, ECG changes and renal failure, has occurred in patients taking ACE inhibitors. Proposed mechanisms include decreased renal elimination of lithium due to decreased aldosterone secretion or decreased renal function.||Lithium should generally not be given with ACE inhibitors. Use of cilazapril with lithium is not recommended, but if the combination proves necessary, careful and frequent monitoring of serum lithium levels should be performed.|
|Non-steroidal anti-inflammatory medicinal products (NSAIDs) including aspirin ≥ 3 g/day||CT||When ACE inhibitors, including INHIBACE, are administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non-selective NSAIDs), attenuation of the antihypertensive effect may occur. Concomitant use of ACE inhibitors, including INHIBACE, and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function. The introduction of therapy with cilazapril (2.5 mg once daily) in hypertensive patients receiving indomethacin (50 mg twice daily) did not result in a reduction in blood pressure. However, the introduction of therapy with indomethacin (50 mg twice daily) in hypertensive patients receiving cilazapril (2.5 mg once daily) did not attenuate the blood pressure lowering effects of cilazapril. The interaction does not appear to occur in patients treated with cilazapril prior to the administration of a NSAID. There was no evidence of a pharmacokinetic interaction between cilazapril and indomethacin.||The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring for signs of worsening heart failure or renal function or loss of blood pressure control after initiation of concomitant therapy, and periodically thereafter.|
|Other antihypertensive agents||CT||An additive effect may be observed when INHIBACE is administered in combination with other blood pressure-lowering agents (e.g., diuretics, beta-adrenergic blocking drugs). |
Agents affecting sympathetic activity (e.g., ganglionic blocking agents or adrenergic neuron blocking agents) should be used with caution.
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.
|These drugs should be introduced at a low initial dosage, and used with caution. |
Close monitoring of blood pressure is advised and dose/regimen adjustment should be considered if necessary.
|Tricyclic antidepressants/antipsy chotics/anesthetics/narcotics||C||Concomitant use of anesthetics during the course of general anesthesia, as well as tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see WARNINGS AND PRECAUTIONS).||Close monitoring of blood pressure is advised and dose/regimen adjustment should be considered if necessary.|
|Dual blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren-containing drugs||CT||Dual Blockade of the Renin-Angiotensin-System (RAS) with ACE inhibitors, ARBs or aliskiren containing drugs is contraindicated in patients with diabetes and/or renal impairment, and is generally not recommended in other patients, since such treatment has been associated with an increased incidence of severe hypotension, renal failure, and hyperkalemia.||See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, Dual Blockade of the Renin-Angiotensin-System (RAS).|
|mTOR inhibitors||C, RCS||Concomitant use of ACE inhibitors with mTOR inhibitors may lead to an increased risk for Angioedema.||See WARNINGS AND PRECAUTIONS, Cardiovascular, Angioedema|
Legend: C = Case Study; RCS = Retrospective Cohort Study; CT = Clinical Trial; T = Theoretical, CT*: Epidemiological studies.
Dosage and Administration
Dosage of INHIBACE (cilazapril) must be individualized.
Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and other pertinent clinical factors. The dosage of other antihypertensive agents being used with INHIBACE may need to be adjusted.
The dose should always be taken at about the same time each day.
Recommended Dose and Dosage Adjustment
The recommended initial dose of INHIBACE is 2.5 mg once daily. Dosage should be adjusted according to blood pressure response, generally, at intervals of at least two weeks. The usual dose range for INHIBACE is 2.5 to 5 mg once daily. Minimal additional blood pressure lowering effects were achieved with a dose of 10 mg once daily. A dose of 10 mg should not be exceeded.
In most patients, the antihypertensive effect of INHIBACE is maintained with a once a day dosing regimen. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, either twice daily administration with the same total daily dose, or an increase in dose should be considered. If blood pressure is not adequately controlled with INHIBACE alone a non-potassium- sparing diuretic may be administered concomitantly. After the addition of a diuretic, it may be possible to reduce the dose of INHIBACE.
Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, salt and/or volume depletion, cardiac decompensation or severe hypertension) may experience an excessive drop in blood pressure following the initial dose. A lower starting dose of 0.5 mg once daily is recommended in such patients and the initiation of treatment should take place under medical supervision.
Concomitant Diuretic Therapy
In patients receiving diuretics, INHIBACE therapy should be initiated with caution, since they are usually volume depleted and more likely to experience hypotension following ACE inhibition. Whenever possible, all diuretics should be discontinued two to three days prior to the administration of INHIBACE to reduce the likelihood of hypotension (see WARNINGS AND PRECAUTIONS). If this is not possible because of the patient’s condition, INHIBACE should be started at 0.5 mg once daily and the blood pressure closely monitored after the first dose until stabilized. Thereafter, the dose should be adjusted according to individual response.
Dosage in Elderly Patients (Over 65 Years)
INHIBACE treatment should be initiated with 1.25 mg (half of a 2.5 mg tablet) once daily or less, depending on the patient’s volume status and general condition. Thereafter, the dose of INHIBACE must be adjusted according to individual tolerability, response, and clinical status.
Dosage Adjustment in Renal Impairment
(see WARNINGS AND PRECAUTIONS, Immune, Anaphylactoid Reactions during Membrane Exposure)
See Table 2 for the dose schedules recommended in patients with hypertension.
|Creatinine Clearance||Initial Dose of INHIBACE||Maximal Dose of INHIBACE|
|> 40 mL/min||1 mg once daily||5 mg once daily|
|10-40 mL/min||0.5 mg once daily||2.5 mg once daily|
|< 10 mL/min||Not recommended.|
Dosage Adjustment in Hepatic Impairment
In patients with liver cirrhosis (but without ascites) who require therapy for hypertension, cilazapril should be dosed with great caution not exceeding 0.5 mg/day accompanied by a careful monitoring of the blood pressure, because severe hypotension may occur. In patients with ascites, cilazapril administration is not recommended (see WARNINGS AND PRECAUTIONS).
Congestive Heart Failure
INHIBACE can be used as adjunctive therapy with digitalis and/or diuretics in patients with congestive heart failure. Therapy should be initiated under close medical supervision. Blood pressure and renal function should be monitored both before and during treatment with INHIBACE because severe hypotension and more rarely, renal failure have been reported (see WARNINGS and PRECAUTIONS).
Initiation of therapy requires consideration of recent diuretic therapy and the possibility of severe salt/volume depletion. If possible, the dose of diuretic should be reduced before beginning treatment, to reduce the likelihood of hypotension. Serum potassium should also be monitored (see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS).
Therapy with INHIBACE should be initiated with a recommended starting dose of 0.5 mg once daily under close medical supervision. In elderly patients with congestive heart failure onhigh diuretic dosage the recommended starting dose of INHIBACE 0.5 mg must be strictly followed (see WARNINGS AND PRECAUTIONS).
The dose should be increased to the lowest maintenance dose of 1 mg daily, usually within a 5 day period, according to tolerability and clinical status. Further titration within the usual maintenance dose of 1 mg to 2.5 mg daily should be carried out based on patients response, clinical status and tolerability.
The usual maximum dose is 2.5 mg once daily. A few patients have been titrated to 5 mg once daily with some additional benefits being achieved. However only limited data is available in congestive heart failure patients treated with 5 mg once daily.
Dosage Adjustment in Patients with Congestive Heart Failure and Renal Impairment or Hyponatremia
Reduced dosage may be required for patients with congestive heart failure and renal impairment or hyponatremia depending on the creatinine clearance. See Table 3 below.
|Creatinine Clearance||Initial Dose of INHIBACE||Maximal Dose of INHIBACE|
|> 40 mL/min||0.5 mg once daily||2.5 mg once daily|
|10-40 mL/min||0.25 - 0.5 mg once daily||2.5 mg once daily|
|< 10 mL/min="2"||Not recommended.|
Limited data are available with regard to overdosage in humans. Symptoms associated with overdosage of ACE inhibitors may include hypotension, which may be severe, circulatory shock, electrolyte disturbances including hyperkalaemia and hyponatraemia, renal impairment with metabolic acidosis, renal failure, hyperventilation, tachycardia, palpitations, bradycardia, dizziness, anxiety and cough.
The recommended treatment of overdosage is intravenous infusion of sodium chloride 9 mg/ml (0.9%) solution. If hypotension occurs, the patient should be placed in the shock position. If available, treatment with angiotensin II infusion and/or intravenous catecholamines may also be considered. Specific therapy with angiotensinamide may be considered if conventional therapy is ineffective.
Pacemaker therapy is indicated for therapy-resistant bradycardia. Vital signs, serum electrolytes and creatinine concentrations should be monitored continuously.
Hemodialysis removes cilazapril and cilazaprilat from the general circulation to a limited extent.
|For management of a suspected drug overdose, contact your regional Poison Control Centre.|
Action and Clinical Pharmacology
Mechanism of Action / Pharmacodynamics
INHIBACE (cilazapril) is an angiotensin converting enzyme (ACE) inhibitor, which is used in the treatment of hypertension and congestive heart failure.
INHIBACE suppresses the renin-angiotensin-aldosterone system and thereby reduces both supine and standing systolic and diastolic blood pressures. Renin is an enzyme that is released by the kidneys into the circulation to stimulate the production of angiotensin I, an inactive decapeptide. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent vasoconstrictor. Angiotensin II also stimulates aldosterone secretion, leading to sodium and fluid retention. After absorption, cilazapril, a pro-drug, is hydrolysed to cilazaprilat, the active metabolite, which prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE. Following the administration of INHIBACE, plasma ACE activity is inhibited more than 90% within two hours at therapeutic doses. Plasma renin activity (PRA) and angiotensin I concentrations are increased and angiotensin II concentrations and aldosterone secretion are decreased. The increase in PRA comes as a result of the loss of negative feedback on renin release caused by the reduction in angiotensin II. The decreased aldosterone secretion may lead to small increases in serum potassium along with sodium and fluid loss. In patients with normal renal function, serum potassium usually remains within the normal range during INHIBACE treatment. Mean serum potassium values increased by 0.02 mEq/L in patients with a normal baseline serum creatinine and by 0.11 mEq/L in patients with a raised serum creatinine. In patients concomitantly taking potassium-sparing diuretics, potassium levels may rise.
ACE is identical to kininase II. Therefore, INHIBACE may interfere with the degradation of the vasodepressor peptide bradykinin. The role that this plays in the therapeutic effects of INHIBACE is unknown.
The antihypertensive effect of INHIBACE is usually apparent within the first hour after administration, with maximum effect observed between three and seven hours after dosing. Supine and standing heart rates remain unchanged. Reflex tachycardia has not been observed. Small, clinically insignificant alterations of heart rate may occur.
At recommended doses, the effect of INHIBACE in hypertensive patients and in patients with congestive heart failure is maintained for up to 24 hours. In some patients, blood pressure reduction may diminish toward the end of the dosage interval. Blood pressure should be assessed after two to four weeks of therapy, and dosage adjusted if required. The antihypertensive effect of INHIBACE is maintained during long-term therapy. No rapid increase in blood pressure has been observed after abrupt withdrawal of INHIBACE.
The antihypertensive effect of angiotensin converting enzyme inhibitors, including INHIBACE is generally lower in black patients than in non-blacks. Racial differences in response are no longer evident when cilazapril is administered in combination with hydrochlorothiazide.
In hypertensive patients with moderate to severe renal impairment, the glomerular filtration rate and renal blood flow remained in general unchanged with INHIBACE.
Congestive Heart Failure
In patients with congestive heart failure the renin-angiotensin-aldosterone and the sympathetic nervous systems are generally activated leading to enhanced systemic vasoconstriction and to the promotion of sodium and water retention. By suppressing the renin-angiotensin-aldosterone system, INHIBACE improves loading conditions in the failing heart by reducing systemic vascular resistance (afterload) and pulmonary capillary wedge pressure (preload) in patients on diuretics and/or digitalis. The onset of action of INHIBACE occurs within 1-2 hours, reaching its maximum effect within 2-4 hours after the first dose. The exercise tolerance of these patients was increased and was associated with an improvement of clinical symptomatology. Patients studied belonged primarily to New York Heart Association Class II and III. The effect of INHIBACE on survival in patients with heart failure has not been evaluated.
Cilazapril is well absorbed and rapidly converted to the active form, cilazaprilat. Peak plasma concentrations, and times to peak plasma concentrations for cilazapril and cilazaprilat following the oral administration of 0.5 to 5 mg cilazapril are given below.
|Oral Dose |
Maximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.
Maximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.
The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%). Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.
Cilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%. Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.
Half-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively. These data suggest the saturable binding of cilazaprilat to ACE. The early elimination phase corresponds to the clearance of free drug. During the terminal elimination phase, almost all of the drug is bound to enzyme. Following the oral administration of 0.5, 1, 2.5 and 5 mg cilazapril, terminal elimination phase half-lives for cilazaprilat are 48.9, 39.8, 38.5 and 35.8 h respectively.
After multiple dose, daily administration of 2.5 mg cilazapril for 8 days, pharmacokinetic parameter values for intact cilazapril after the last dose are similar to the first dose. For cilazaprilat, peak plasma concentrations are achieved at the same time but are 30% higher after the last dose. Trough plasma concentrations and areas under the curve are 20% higher. The terminal elimination phase half -life after the last dose is 53.8 h. The effective half-life of accumulation for cilazaprilat is 8.9 h.
Special Populations and Conditions
Congestive Heart Failure
In patients with congestive heart failure the clearance of cilazaprilat is correlated with the creatinine clearance. Thus, dosage adjustments beyond those recommended for patients with impaired renal functions (see DOSAGE AND ADMINISTRATION, Congestive Heart Failure) should not be necessary.
Following the administration of 1 mg cilazapril to healthy elderly and young volunteers, the elderly group experienced greater peak plasma concentrations of cilazaprilat and areas under the curve (39% and 25%, respectively) and lower total clearance and renal clearance (20% and 28%, respectively) than the younger volunteers.
Following the administration of 1 mg cilazapril in patients with moderate to severe compensated liver cirrhosis, peak plasma concentrations of cilazapril and cilazaprilat are increased (57% and 28% respectively), attained 30 minutes and 45 minutes earlier, and total clearances are decreased (51% and 31% respectively), in comparison to healthy subjects. The renal clearance and early and terminal elimination phase half-lives of cilazaprilat are decreased 52%, 42% and 62% respectively.
In patients with renal impairment, peak plasma concentrations of cilazaprilat, times to peak plasma concentrations, early elimination phase half-lives, areas under the curve and 24 hour plasma concentrations all increase as creatinine clearance decreases. The changes in these parameters are small for patients with creatinine clearances of 40 mL/min or more. Cilazaprilat clearance (total and renal) decreases in parallel with creatinine clearance. Cilazaprilat is not eliminated in patients with complete renal failure. Hemodialysis reduces concentrations of both cilazapril and cilazaprilat to a limited extent.
Storage and Stability
Store 15-30 ºC. Keep container tightly closed.
Special Handling Instructions
The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater, and disposal through household waste should be avoided. Use established ‘collection systems' if available in your location.
Dosage Forms, Composition and Packaging
INHIBACE (cilazapril) is available in film-coated tablets containing:
- 2.5 mg cilazapril - pinkish-brown, oval shaped, single scored biconvex tablets, imprinted CIL 2,5. Available in bottles of 100 tablets and blister packs of 28 tablets.
- 5 mg cilazapril - reddish-brown, oval shaped, single scored biconvex tablets, imprinted CIL 5. Available in bottles of 100 tablets and blister packs of 28 tablets.
INHIBACE 2.5 mg and 5 mg film-coated tablets contain 2.5 mg and 5 mg anhydrous cilazapril, as cilazapril monohydrate, respectively. Non-medicinal ingredients: the tablets also contain lactose monohydrate, cornstarch, hydroxypropyl methylcellulose, talc, sodium stearyl fumarate and titanium dioxide. Iron oxide is present as the colouring agent in the 2.5 mg and 5 mg tablets.